Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
| dc.rights.license | open | en_US |
| dc.contributor.author | GALMICHE, Simon | |
| dc.contributor.author | LUONG NGUYEN, Liem Binh | |
| dc.contributor.author | TARTOUR, Eric | |
| dc.contributor.author | DE LAMBALLERIE, Xavier | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | WITTKOP, Linda | |
| dc.contributor.author | LOUBET, Paul | |
| dc.contributor.author | LAUNAY, Odile | |
| dc.date.accessioned | 2022-01-20T08:22:07Z | |
| dc.date.available | 2022-01-20T08:22:07Z | |
| dc.date.issued | 2021-09-29 | |
| dc.identifier.issn | 1198-743X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/124444 | |
| dc.description.abstractEn | BACKGROUND: Available data show that COVID-19 vaccines may be less effective in immunocompromised populations, who are at increased risk of severe COVID-19. OBJECTIVES: We conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations. DATA SOURCES :We searched Medline and Embase databases. STUDY ELIGIBILITY CRITERIA, PATIENTS, INTERVENTIONS: We included studies of COVID-19 vaccines after complete vaccination in immunocompromised patients until 31 August 2021. Studies with <10 patients, safety data only and case series of breakthrough infections were excluded. METHODS: Risk of bias was assessed via the tool developed by the National Institutes of Health on interventional and observational studies. Immunogenicity was assessed through non-response rate defined as no anti-SARS-CoV-2 spike protein antibodies, efficacy and effectiveness by the relative reduction in risk of SARS-CoV-2 infection or COVID-19. We collected factors associated with the risk of non-response. We presented collected data by immunosuppression type. RESULTS: We screened 5917 results, included 162 studies. There were 157 on immunogenicity in 25 209 participants, including 7835 cancer or haematological malignancy patients (31.1%), 6302 patients on dialysis (25.0%), 5974 solid organ transplant recipients (23.7%) and 4680 immune-mediated disease patients (18.6%). Proportion of non-responders seemed higher among solid organ transplant recipients (range 18–100%) and patients with haematological malignancy (range 14–61%), and lower in patients with cancer (range 2–36%) and patients on dialysis (range 2–30%). Risk factors for non-response included older age, use of corticosteroids, immunosuppressive or anti-CD20 agent. Ten studies evaluated immunogenicity of an additional dose. Five studies evaluated vaccine efficacy or effectiveness: three on SARS-CoV-2 infection (range 71–81%), one on COVID-19-related hospitalization (62.9%), one had a too small sample size. CONCLUSIONS: This systematic review highlights the risk of low immunogenicity of COVID-19 vaccines in immunocompromised populations, especially solid organ transplant recipients and patients with haematological malignancy. Despite lack of vaccine effectiveness data, enhanced vaccine regimens may be necessary. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Cancer | |
| dc.subject.en | COVID-19 | |
| dc.subject.en | Dialysis | |
| dc.subject.en | Effectiveness | |
| dc.subject.en | Efficacy | |
| dc.subject.en | Immunogenicity | |
| dc.subject.en | SARS-CoV-2 immunocompromised | |
| dc.subject.en | Solid organ transplant | |
| dc.subject.en | Vaccine | |
| dc.title.en | Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.cmi.2021.09.036 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 35020589 | en_US |
| bordeaux.journal | Clinical Microbiology and Infection | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | MORPH3Eus | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Microbiology%20and%20Infection&rft.date=2021-09-29&rft.eissn=1198-743X&rft.issn=1198-743X&rft.au=GALMICHE,%20Simon&LUONG%20NGUYEN,%20Liem%20Binh&TARTOUR,%20Eric&DE%20LAMBALLERIE,%20Xavier&WITTKOP,%20Linda&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||